Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05918783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

StatusRecruiting
PhasePhase 1
Started2025-05-28
View on ClinicalTrials.gov ↗
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.

Amendment record

Amended 5 times since 2023-06-15; most recent filed 2025-02-10. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.

2025-02-10
Amendment Study Status v5
2024-10-29
Amendment Suspended→Recruiting Study Status, Contacts/Locations v4
2024-10-01
Amendment Not Yet Recruiting→Suspended Study Status, Contacts/Locations v3
2024-03-04
Amendment Study Status v2
2023-08-28
Amendment Study Identification, Study Status, Sponsor/Collaborators v1
2023-06-15
Original filing
Trial Details
NCT Number NCT05918783
Lead Sponsor Impact Biotech Ltd
Conditions Peripheral Lung Tumor
Enrollment 36 participants
Start Date 2025-05-28
Primary Completion 2027-05-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-11